CTRI/2009/091/000598招募中2 期
A 12-week multi-center, randomized, double-blind, placebocontrolled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of fivedoses of LCQ908 (2, 5, 10, 15 and 20 mg) or sitagliptin 100mg on a background therapy of metformin in obese patients with type 2 diabetes
ovartis Healthcare Private Limited0 个研究点目标入组 720 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 720
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Written informed consent to participate in the study, before any study related activities are performed, and is likely to comply with all study requirements, including dietary guidelines.
- •2. Age 18-75 years, inclusive.
- •3. Males, non-fertile females, and females of non-childbearing potential. Women must be (a) postmenopausal, defined as age >48 with 12 months of natural (i.e.
- •spontaneous) amenorrhea or age >42 with >6 months of spontaneous amenorrhea with serum FSH levels > 30 mIU/mL and estradiol <30 pg/ml ; (b) 6 weeks post-surgical
- •bilateral oophorectomy with or without hysterectomy; or (c) have a documented history of tubal ligation at least 1 year prior to screening.
- •4. Patients with T2DM with HbA1c 7.0 to 10.0%, inclusive, at Visit 1.
- •5. Fasting plasma glucose ≤250mg/dL (13.9 mmol/L) at Visit 1 assessed by the central laboratory
- •6. Patients treated with metformin for at least three months prior to Visit 1 (screening) and on a stable dose ≥1500 mg for 4 weeks prior to Visit 3 (randomization). Patients must agree to maintain the same dose of metformin from 4 weeks before Visit 3 to the end of the study.
- •7. Body mass index (BMI) of 28 to 42 kg/m2 inclusive
- •8. Body weight at Visit 1 within 5% of their self-reported weight over the past three months and agreement to maintain the study-recommended diet (counseled during screening) and usual exercise habits during the full course of the study.
- •9. Patients on stable doses of statins or fibrates for 6 weeks prior to Visit 1 must agree to maintain those doses during the study period.
排除标准
- •1. A history of type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g. Cushings syndrome and acromegaly
- •2. A history of acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months.
- •3. Evidence of significant diabetic complications, e.g., symptomatic autonomic neuropathy, severe diabetic retinopathy (e.g. associated with retinal hemorrhages or repeated photocoagulation therapy), diabetic gastroparesis or enteropathy.
- •4. Treatment with any oral antidiabetic agent other than metformin within 12 weeks prior to Visit 1.
- •5. Chronic insulin treatment ( greater than 1 week of treatment in the absence of concurrent illness)within the 6 months prior to Visit 1.
- •6. Acute infections which may affect blood glucose control 4 weeks prior to Visit 1 and other concurrent medical conditions that may interfere with the interpretation of efficacy and safety during the study.
- •7. Donation of one unit (500 ml) or more of blood, significant blood loss equaling at least one unit of blood within 2 weeks, or a blood transfusion within 8 weeks prior to Visit 1
- •8. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive
- •hCG laboratory test (greater than 5 mI U mL).
- •9. Severe illness, trauma, or major surgery within 3 months prior to Visit 1.
- •10. Mean (of the last 2 of 3 consecutive determinations) sitting diastolic blood pressure greater than 100 mmHg and or mean sitting systolic blood pressure greater than 150 mmHg. (patients may be rescreened on one occasion only no sooner than 4 weeks after adjustment of antihypertensive medications)
- •11. History of Congestive Heart Failure (New York Heart Association (NYHA) Class IIIIV) or pacemaker use within the past 5 years.
- •12. Any of the following within the past 12 months
- •a. Myocardial infarction (MI). If the Visit 1 ECG reveals patterns consistent with a MI in the absence of clinical signs and symptoms of acute MI and in the absence of elevated troponin and CK-MB enzymes and the date of the event can not be determined, then the patient can enter the trial at the discretion of the investigator andoror local medical monitor
- •b. Unstable angina
- •c. Arterial revascularization, coronary artery bypass graft surgery, or percutaneous coronary intervention
- •d. Cerebrovascular accident or recurrent transient ischemic attacks
- •13. Any of the following ECG abnormalities
- •a. Torsades de pointes, sustained and clinically relevant atrial or ventricular tachycardia, or atrial or ventricular fibrillation
- •b. Second degree AV block (Mobitz 1 and 2)
- •c. Third degree AV block
- •d. Prolonged QTc (greater than 450 ms for males and greater than 470 ms for females) at screening confirmed by visual inspection of the electrocardiogram
- •14. Liver disease such as cirrhosis or chronic active hepatitis B and C
- •15. Impaired renal function including a history of dialysis or of nephrotic syndrome and or estimated creatinine clearance less than 50 ml per min (using the Modification of Diet in
- •Renal Disease (MDRD) formula). Proteinuria less than 300 mg per gram creatinine will be allowed.
- •16. Any of the following significant laboratory abnormalities at Visit 1
- •a. Alanine ami
研究者
相似试验
已完成
不适用
A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5, 10, 15 and 20 mg) or sitagliptin 100 mg on a background therapy of metformin in obese patients with type 2 diabetes-E11 Non-insulin-dependent diabetes mellitusNon-insulin-dependent diabetes mellitusE11PER-075-09OVARTIS BIOSCIENSES PERU S.A.,
进行中（未招募）
不适用
Efficacy, safety and tolerability of the co-administration of NVA237 + indacaterol once daily vs. indacaterol once daily in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-005673-23-GRovartis Pharma Service AG450
进行中（未招募）
不适用
Efficacy, safety and tolerability of the co-administration of NVA237 + indacaterol once daily vs. indacaterol once daily in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-005673-23-IEovartis Pharma Service AG450
进行中（未招募）
不适用
A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5, 10, 15 and 20 mg) or sitagliptin 100 mg on a background therapy of metformin in obese patients with type 2 diabetesType II DiabetesMedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2009-009888-60-BEovartis Pharma Services AG720
进行中（未招募）
不适用
A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5, 10, 15 and 20 mg) or sitagliptin 100 mg on a background therapy of metformin in obese patients with type 2 diabetesType II DiabetesMedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2009-009888-60-DEovartis Pharma Services AG720